Genentech, Inc.
South San Francisco, CA, US· latest recorded location
Genentech, Inc. is named on 3,311 US grants and 4,044 published applications in this corpus. Its most frequent classification is C07K (Peptides).
- Granted patents
- 3,311
- Published applications
- 4,044
- Inventors
- 4,012
- Granted in 2026 so far
- 70
- Most recent grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 4 | 0 |
| 1983 | 2 | 0 |
| 1984 | 4 | 0 |
| 1985 | 9 | 0 |
| 1986 | 9 | 0 |
| 1987 | 13 | 0 |
| 1988 | 12 | 0 |
| 1989 | 17 | 0 |
| 1990 | 20 | 0 |
| 1991 | 21 | 0 |
| 1992 | 35 | 0 |
| 1993 | 38 | 0 |
| 1994 | 28 | 0 |
| 1995 | 30 | 0 |
| 1996 | 45 | 0 |
| 1997 | 82 | 0 |
| 1998 | 128 | 0 |
| 1999 | 53 | 0 |
| 2000 | 72 | 0 |
| 2001 | 70 | 3 |
| 2002 | 70 | 26 |
| 2003 | 70 | 200 |
| 2004 | 65 | 56 |
| 2005 | 69 | 91 |
| 2006 | 137 | 106 |
| 2007 | 274 | 185 |
| 2008 | 221 | 119 |
| 2009 | 83 | 141 |
| 2010 | 122 | 123 |
| 2011 | 79 | 157 |
| 2012 | 105 | 129 |
| 2013 | 107 | 178 |
| 2014 | 107 | 216 |
| 2015 | 78 | 171 |
| 2016 | 88 | 208 |
| 2017 | 99 | 207 |
| 2018 | 129 | 216 |
| 2019 | 99 | 189 |
| 2020 | 111 | 193 |
| 2021 | 104 | 171 |
| 2022 | 64 | 166 |
| 2023 | 77 | 205 |
| 2024 | 86 | 236 |
| 2025 | 105 | 200 |
| 2026 | 70 | 152 |
By publication year. 2026 runs to 8 Oct.
Technology areas
Share of 7,355 documents
- C07KPeptides5,055
- A61KMedicines and medical preparations4,982
- A61PTherapeutic uses of medicines4,576
- G01NInvestigating or analysing materials by determining their chemical or physical properties1,674
- C12NMicroorganisms or enzymes1,484
- C07DHeterocyclic compounds1,206
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms777
- Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests758
- C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition654
- Y02ATechnologies for adaptation to climate change284
Recent patents
- CDK inhibitors6 Oct 2026US 12,751,951 B2
- Compositions and methods of treating lupus nephritis6 Oct 2026US 12,752,005 B2
- Medical syringe6 Oct 2026US D1,151,996 S1Design
- Medical syringe6 Oct 2026US D1,151,997 S1Design
- Machine learning enabled prediction of molecular structures and properties29 Sep 2026US 12,749,554 B2
- Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase8 Oct 2026US 2026/0306487 A1
- Solid forms of 1-((S)-4-((R)-7-(6-amino-4-methyl-3-(trifluoromethyl)pyridin-2-yl)-6-chloro-8-fluoro-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)quinazolin-4-yl)-3-methylpiperazin-1-yl)prop-2-en-1-one8 Oct 2026US 2026/0308144 A1
- Methods and compositions for treating cancer8 Oct 2026US 2026/0308241 A1
- Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof8 Oct 2026US 2026/0308274 A1
- Modified guide rnas8 Oct 2026US 2026/0308577 A1
Most cited
By later US patents